Skip to main content
. 2018 Feb 12;10(2):201. doi: 10.3390/nu10020201

Table 3.

Short chain fatty acids (SCFAs) concentration in faecal samples before (T0) and after (T1) the intervention, expressed by means ± SEM and by μmol/g of faeces.

SCFA Placebo Group Synergy 1 Group Placebo: T0 vs. T1 2 Synergy 1: T0 vs. T1 T1: Placebo vs. Synergy 1 3
T0 T1 T0 T1
Acetic 29.84 ± 1.93 28.82 ± 4.26 30.00 ± 3.35 44.06 1 ± 4.13 0.520 0.047 * 0.020 *
Propionic 9.91 ± 1.23 7.97 ± 1.55 10.16 ± 1.25 11.14 ± 0.61 0.692 0.328 0.048 *
Iso-butyric 1.41 ± 0.15 1.56 ± 0.33 1.60 ± 0.14 1.33 ± 0.13 0.678 0.059 1.000
Butyric 8.92 ± 1.37 8.21 ± 1.89 8.02 ± 1.27 10.41 ± 0.89 0.889 0.047 * 0.292
Iso-valeric 1.43 ± 0.18 1.46 ± 0.23 1.72 ± 0.19 1.56 ± 0.16 0.515 0.400 0.419
Valeric 1.55 ± 0.21 0.97 ± 0.16 1.72 ± 0.18 1.47 ± 0.18 0.030 * 0.123 0.062
Total SCFAs 53.06 ± 5.52 48.99 ± 5.22 53.23 ± 6.94 69.95 ± 5.92 0.418 0.041 * 0.005 *
Total BCFAs 2.84 ± 0.30 3.02 ± 0.40 3.32 ± 0.33 2.89 ± 0.28 0.765 0.132 0.679
Relative BCFAs 1 5.35 6.16 6.24 4.13

* p < 0.05. 1 Relative concentration of the total branched-chain fatty acids (BCFAs) (sum of iso-butyic and iso-valeric acids) expressed as a percentage of the total SCFA. 2 Comparison between groups using Student’s t-test or the Mann–Whitney U test, as appropriate. 3 Comparison within groups before and after intervention using the Student’s t-test or the Wilcoxon test, as appropriate.